SABCS 2019: Updates in HER2+ Breast Cancer | Priority Report

Taxane Choice With Pertuzumab/Trastuzumab in HER2+ MBC Does Not Affect Outcome

December 20, 2019

The combination of pertuzumab and trastuzumab plus paclitaxel is commonly being used in the community for the treatment of patients with HER2-positive breast cancer, and appears to be as effective as pertuzumab and trastuzumab plus docetaxel according to real-world findings from a retrospective cohort study.

Adjuvant T-DM1 Benefit in HER2+ Breast Cancer Observed Across Key Subgroups

December 14, 2019

The invasive disease-free survival benefit with adjuvant T-DM1 versus trastuzumab in patients with HER2-positive early breast cancer who had residual invasive disease following neoadjuvant therapy was observed regardless of the type of neoadjuvant chemotherapy used.

Subcutaneous Fixed-Dose Pertuzumab/Trastuzumab Proves Noninferiority Versus IV Drugs

December 13, 2019

A subcutaneous fixed-dose combination of pertuzumab and trastuzumab demonstrated noninferiority to intravenous formulations of the 2 drugs with respect to pharmacokinetics, clinical activity, and safety, a randomized trial demonstrated.